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Abstract
Rationale Calcineurin is a protein regulating cytokine expression in T lymphocytes and calcineurin inhibitors such as cyclo-
sporine A (CsA) are widely used for immunosuppressive therapy. It also plays a functional role in distinct neuronal processes in
the central nervous system. Disturbed information processing as seen in neuropsychiatric disorders is reflected by deficient
sensorimotor gating, assessed as prepulse inhibition (PPI) of the acoustic startle response (ASR).
Objective Patients who require treatment with immunosuppressive drugs frequently display neuropsychiatric alterations during
treatment with calcineurin inhibitors. Importantly, knockout of calcineurin in the forebrain of mice is associated with cognitive
impairments and symptoms of schizophrenia-like psychosis as seen after treatment with stimulants.
Methods The present study investigated in rats effects of systemic acute and subchronic administration of CsA on sensorimotor
gating. Following a single injection with effective doses of CsA, adult healthy male Dark Agouti rats were tested for PPI. For
subchronic treatment, rats were injected daily with the same doses of CsA for 1 week before PPI was assessed. Since calcineurin
works as a modulator of the dopamine pathway, activity of the enzyme tyrosine hydroxylase was measured in the prefrontal
cortex and striatum after accomplishment of the study.
Results Acute and subchronic treatment with the calcineurin inhibitor CsA disrupted PPI at a dose of 20 mg/kg. Concomitantly,
following acute CsA treatment, tyrosine hydroxylase activity was reduced in the prefrontal cortex, which suggests that dopamine
synthesis was downregulated, potentially reflecting a stimulatory impact of CsA on this neurotransmitter system.
Conclusions The results support experimental and clinical evidence linking impaired calcineurin signaling in the central nervous
system to the pathophysiology of neuropsychiatric symptoms. Moreover, these findings suggest that therapy with calcineurin
inhibitors may be a risk factor for developing neurobehavioral alterations as observed after the abuse of psychomotor stimulant
drugs.
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Introduction
Disruptions in attention and cognition are seen in patients with
idiopathic schizophrenia and during psychotic states induced
by stimulants, such asmethamphetamine (Druhan et al. 1998).
Impairments in sensorimotor gating, the ability of an organism
to filter irrelevant sensory information, are evident in these
patients, as well (Geyer et al. 2001). Sensorimotor gating is
measured as prepulse inhibition (PPI) of the acoustic startle
response (ASR) and uses almost identical procedures in
humans and rodents (Braff et al. 2001; Koch 1999;
Swerdlow et al. 2001; Swerdlow et al. 2000). Schizophrenic
patients show impairment in PPI and similar deficits can be
produced in rats experimentally by a variety of drugs, e.g.,
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dopamine receptor agonists such as methamphetamine (Geyer
et al. 2001; Hadamitzky et al. 2011; Hutchison and Swift
1999). While experimentally induced PPI deficits are clearly
not animal models of schizophrenia or stimulant-induced psy-
chosis, they may serve as endophenotypes or physiological
markers which are associated with the disease (Cadenhead
et al. 2002; Swerdlow et al. 1994, 2000).
Calcineurin is a Ca2+/calmodulin-regulated serine/
threonine protein phosphatase that is widely expressed in the
central nervous system (CNS) and T lymphocytes (Hubbard
and Klee 1989). The most specific and well-known potent
inhibitors of calcineurin are the small-molecule drugs cyclo-
sporine A (CsA) and tacrolimus (FK506). Due to their immu-
nosuppressive action, these compounds are commonly used in
clinical routine for the prevention of graft rejection after kid-
ney, liver, and heart transplantation, as well as for treatment of
inflammatory autoimmune diseases such as rheumatoid arthri-
tis, or psoriasis (Halloran 2004; Lindenfeld et al. 2004; Taylor
et al. 2001). Calcineurin inhibitors interact with cytoplasmic
receptors such as cyclophilins and FK binding proteins
(FKBPs) to form an immunophilin-immunosuppressant com-
plex that binds calcineurin and inhibits its activity by sterically
hindering the access of substrates to the catalytic site (Liu et al.
1992). Blockade of cellular calcineurin in T lymphocytes by
both CsA and FK506 prevents dephosphorylation of the nu-
clear factor of activated T cells (NFAT), its transfer to the
nucleus (Tedesco and Haragsim 2012), and its ability to initi-
ate transcription of interleukin-2 (IL-2), interferon-gamma
(IFN-γ), and related genes (Batiuk and Halloran 1997;
Rusnak and Mertz 2000). In the CNS, calcineurin has been
shown to play an important functional role in distinct process-
es like neurite extension, synaptic plasticity, or learning and
memory (Winder and Sweatt 2001; Zeng et al. 2001).
Despite the known beneficial effects of calcineurin inhibi-
tors and their widespread application in clinical conditions,
little is known about unwanted neuropsychological side ef-
fects of this group of small-molecule immunosuppressants.
Indeed, clinical evidence indicates that in patients treatment
with calcineurin inhibitors may lead to an increased incidence
rate of neuropsychiatric side effects such as disorientation,
depression, aggression, paranoia, or psychosis (Chang et al.
2001; de Groen et al. 1987; Kahan 1994; Kahan et al. 1987;
Lang et al. 2009; Lindenfeld et al. 2004). Moreover, it was
demonstrated in rodents that acute administration of CsA de-
creased calcineurin activity in the brain and resulted in neuro-
behavioral activation, reflected as taste avoidance and elevat-
ed neuronal activity in the insular cortex and the amygdala
(Pacheco-Lopez et al. 2013). Chronic treatment, however, in-
creased levels of anxiety- and depressive-like behavior, and
disturbed social behavior (Mineur et al. 2014; Sato et al.
2007). Importantly, several lines of evidence suggest that al-
tered calcineurin signaling may contribute to the pathogenesis
of schizophrenia or the development of schizophrenia-like
symptoms (Takao and Miyakawa 2006). On one hand,
calcineurin-mutant mice resembled a spectrum of forebrain-
specific abnormalities remarkably similar to that observed in
schizophrenic patients, such as increased locomotor activity,
decreased social interaction, and impairments in prepulse in-
hibition, as well as working memory deficits (Miyakawa et al.
2003; Zeng et al. 2001). On the other hand, investigations
identified a calcineurin-related gene (PPP3CC, which encodes
for the calcineurin-γ subunit) as a potential schizophrenia sus-
ceptibility gene (Gerber et al. 2003). The finding that calcine-
urin is located downstream of the glutamate N-methyl-D-as-
partate (NMDA) receptor signaling pathway and that it works
as a modulator of the dopamine pathway (Lin et al. 2007;
Takao and Miyakawa 2006) strongly suggests a possible as-
sociation between calcineurin signaling and the traditional
theories of schizophrenia pathophysiology: dopamine hyper-
function and/or glutamate hypofunction (Abi-Dargham and
Moore 2016; Laruelle et al. 2003). This hypothesis is further
supported by a case report of a schizophrenic patient, whose
acute exacerbation of symptoms was strongly related to treat-
ment with the calcineurin inhibitor FK506 (Lin et al. 2007).
Evidence indicates that disturbances in frontal cortex dopa-
mine may contribute to the occurrence of psychotic episodes
(Carey et al. 1995), while psychostimulant-induced locomo-
tion, one phenotype for psychotic symptoms in rodents, is
associated with dopaminergic activation in the striatum
(Kesby et al. 2018).
The present study investigated in healthy rats effects of
acute and subchronic treatment with the immunosuppressant
and calcineurin inhibitor CsA on sensorimotor gating. To gain
insight on possible changes in central dopaminergic activity,
the rate-limiting enzyme of dopamine synthesis, tyrosine hy-
droxylase (Daubner et al. 2011), was measured in the prefron-
tal cortex and the striatum.
Methods
Animals
Male Dark Agouti rats (200–230 g, correspondingly 50–
60 days of age), a rat strain widely used in immunological
research (Dimitrijevic et al. 2018), were obtained from
Janvier (Le Genest-Saint-Isle, France) and group housed for
an acclimation period of 1 week with ad libitum access to food
and tap water. The vivarium was temperature (20 °C) and
humidity (55 ± 5%) controlled. To allow the experiments to
be conducted during the active phase of the rats’ awake/sleep
cycle, it was maintained on a reversed 12-h dark, 12-h light
cycle (7:00 a.m. to 7:00 p.m.). During the second week, ani-
mals were gently handled 5 min/day by the person performing
the experiments. The animal facilities as well as the experi-
mental procedures were in accordance with the National
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Institutes of Health and the Association for the Assessment
and Accreditation of Laboratory Animal Care guidelines and
were approved by the Institutional Animal Care and Use
Committee (LANUV Düsseldorf, North Rhine-Westphalia).
Drugs
The calcineurin inhibitor and immunosuppressant CsA
(100 mg/mL; LC Laboratories, Woburn, USA) was dissolved
in 100 μL ethanol (96%) and 900 μL Miglyol (Caelo,
Germany). Prior to intraperitoneal (i.p.) administration, this
stock solution was further diluted with sterile saline (0.9%
NaCl, Braun, Germany) to adjust for the required drug doses
of 5 and 20 mg/kg body weight with an injection volume of
1 mL. Rats of the control groups received an equivolumed,
weight-adapted dose of the stock solution diluted with sterile
saline. The administered doses are based on previous studies,
verifying this drugs’ immunosuppressive properties and effi-
cacy on progress and outcome in animal disease models
(Hadamitzky et al. 2016; Lückemann et al. 2020).
Prepulse inhibition (PPI) of the acoustic startle re-
sponse (ASR)
Sensorimotor gating was assessed as PPI of the ASR using an
automated SRLab startle system (San Diego Instruments, San
Diego, CA, USA) as described elsewhere (Brosda et al. 2011;
Hadamitzky et al. 2011). The sound-attenuated, ventilated
chambers consisted of non-restrictive Plexiglas cylinders
(9 cm in diameter) resting on a platform, mounted above a
sensitive piezoelectric sensor. Vibrations of the cylinder
caused by the whole-body ASR were transduced into analog
signals and digitized and stored on a computer using SRLab
software. At the beginning of each session, animals were
placed into the chambers for a 5-min acclimatization period.
White background noise of 70 dB lasted throughout the ses-
sion. A test session consisted of 100 trials presented in a pseu-
dorandom order with variable inter-trial intervals (7–23 s).
The protocol consisted of 20 pulse-alone white noise trials
with an intensity of 118 dB sound pressure level (startle stim-
ulus; duration 40 ms), 10 prepulse trials (86 dB SPL, duration
20 ms), 10 NoStim trials, and 40 prepulse-pulse trials. The
prepulse-pulse trials consisting of a 118-dB pulse preceded
by a prepulse of 74, 78, 82, or 86 dB (20 ms duration) emitted
120 ms before the pulse onset. At the beginning (startle block
1) and end of the session (startle block 2), 10 pulse-alone trials
were carried out to measure habituation to the startle stimulus.
However, these trials were excluded from startle magnitude
calculations. In general, data was measured during a 100-ms
time window after stimulus onset and averaged for each ani-
mal and trial type. PPI of the ASRwas calculated for prepulse-
pulse trials as a percentage of pulse-alone startle magnitude
((mean startle magnitude for pulse-alone trials−mean startle
magnitudes for prepulse-pulse trials)/mean startle magnitude
for pulse-alone trials) × 100. Startle sessions were ~ 45 min in
duration. After every test session, test chambers were cleaned
with 70% ethanol to eliminate possible odor cues left by pre-
vious animals.
Neurochemical measurement
For brain sample collection, anesthetized animals were eutha-
nized immediately after assessment of PPI; brains were quick-
ly removed, frozen on dry ice, and stored at − 80 °C. Using a
freezing microtome (Microm HM560, Thermo Fisher
Scientific, Walldorf, Germany), coronal brain sections of
200-μm thickness were cut at − 15 °C and placed on pre-
chilled glass slides. Subsequently, the striatum as well as the
prefrontal cortex (PFC; Fig. 1b) was dissected from serial
brain sections using a micropunch technique (Cuello and
Carson 1983). A pre-chilled stainless-steel sample puncher
(internal diameter of 2 mm; Fine Science Tools, Heidelberg,
Germany) was taken to obtain tissue samples of the left and
right PFC and striatum. The optical tract, corpus callosum,
and hippocampus served as anatomical landmarks to ensure
comparable punch positions across animals (Paxinos and
Watson 1998). Punches of each individual animal were
pooled and proteins from the snap-frozen brain tissue were
extracted utilizing freshly made radio-immuno-precipitation
assay buffer (RIPA buffer; sc-24948, Santa Cruz
Biotechnology) according to manufacturer’s protocol.
Protein concentrations were calculated via BCA Protein
Assay (Pierce Thermo scientific). For protein quantification,
30 μg protein per sample was diluted with 1× protein gel
loading buffer (Roti®Load 1, CARL ROTH). Samples were
boiled for 5 min at 95 °C, resolved on 8% SDS-PAGE gels,
transferred to PVDF membranes, and probed with antibodies
specific for TH (#58844), and phosphorylated (p)-TH (#2791)
(both 1:1000, Cell Signaling). Antibody (#3700; 1:1000, Cell
signaling) was used as loading control. Following membranes
were washed and incubated with horseradish peroxidase–
conjugated secondary anti-rabbit or anti-mouse antibodies
((#7074, #7076, both cell signaling). Proteins were visualized
by chemiluminescent using Immobilon Western HRP
Substrate detection reagents (Merck Millipore) on Fusion
Imager (Vilber Lourmat). Protein signals were quantified by
Image Lab™ Software (version 6.0.1, Bio Rad) and normal-
ized for protein abundance of corresponding loading control
β-actin. Sample sizes vary since non-evaluable probes had to
be excluded.
Experimental design
Central and peripheral activity and distribution of CsA 60 min
following acute treatment, as well as after six consecutive
daily i.p. injections of CsA, have already been confirmed
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(Hadamitzky et al. 2016; Pacheco-Lopez et al. 2013; von
Horsten et al. 1998). Based on these findings, the present
study comprised two separate experiments (Fig. 2). In the first
experiment, effects of acute CsA (5 or 20 mg/kg) on sensori-
motor gating were assessed. In a second experiment, the im-
pact of subchronic treatment effects of CsA on sensorimotor
Fig. 1 Experimental design (a).
The study comprised two separate
experiments. In the first
experiment (group I), rats were
tested for PPI of the ASR 60 min
after an acute injection of
cyclosporine A (CsA) at doses of
5 and 20 mg/kg. In the second
experiment, distinct animals were
treated with 5 or 20 mg/kg CsA
for 7 days, once daily, before PPI
of the ASR was assessed 60 min
following the last injection. b
Placement of punches.
Immediately, after
accomplishment of the last PPI
session, respectively, animals
were euthanized, and brains were
quickly removed. As illustrated,
coronal sections were cut on a
cryostat, left and right prefrontal
cortex (left hand series) and
striatum (right hand series) were
dissected from serial brain
sections using a sample corer, and
brain tissue was processed for
protein expression analyses
Fig. 2 Acute treatment with the calcineurin inhibitor and
immunosuppressant cyclosporine A on prepulse inhibition (PPI) of the
acoustic startle response (ASR). The line plot shows percent PPI as a
function of different prepulse intensities above background (a). Groups
treated with CsA (5, 20 mg/kg) displayed diminished mean PPI scores
compared to controls (b), while ASR did not differ between groups (c).
Data are shown as scatter plot with mean ± SEM. Differences between
groups are indicated by asterisk (ANOVA, Bonferroni post hoc;
*p < 0.05; **p < 0.01; n = 8–10/group)
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gating (5 or 20 mg/kg CsA once daily for 7 days) before PPI
was assessed 60 min following the last drug administration.
Since previous works confirmed that group sizes of n = 7–10
are sufficient to gain statistical affects regarding central side
effects of small-molecule immunosuppressive drugs
(Hadamitzky et al. 2014, 2018; von Horsten et al. 1998), sim-
ilar group sizes were used in the present approach. PPI testing
was always performed under red-light illumination during the
activity period of the animals. Thirty minutes prior to testing,
animals were transferred to the experimental room to allow
acclimation to the new surroundings. After each test session,
the Plexiglas cylinders in the startle chambers were cleaned
with 70% ethanol to eliminate possible odor cues left by pre-
vious animals. Immediately, after accomplishment of the last
PPI session, respectively, animals were euthanized, and brains
were removed, and processed for protein expression.
Data analyses
The descriptive statistics are based on means, and variance is
indicated by the standard error of the mean (SEM). Statistical
analyses were conducted using SigmaPlot software (Version
12.3, SPSS, Chicago, IL, USA) and the level of significance
was set at p < 0.05. Multiple dose experiments were analyzed
using one-way analysis of variance (ANOVA) followed by
Bonferroni corrections for pairwise comparisons.
Results
Prepulse inhibition of the acoustic startle response
after acute treatment with CsA
ANOVA showed an effect for the factor treatment (F(2,81) =
3.545; p = 0.043) and for the factor prepulse (F(3,81) =
44.057; p < 0.001), but no treatment × prepulse interaction
(F(6,81) = 0.989; p = 0.438), following acute injections with
the immunosuppressant and the calcineurin inhibitor CsA
(Fig. 2a). ANOVA also revealed a treatment effect on mean
PPI calculated as average of all four prepulse conditions
(F(2,117) = 5.395; p = 0.006). Post hoc testing revealed that
mean PPI in animals treated with 5 mg/kg CsA (p = 0.033)
and 20mg/kg CsA (p = 0.009) was significantly reduced com-
pared to vehicle controls (Fig. 2b). Acute CsA had no effect
onmeanASR (ANOVA; [F(2,27) = 1.31; p = 0.286]; Fig. 2c).
Tyrosine hydroxylase levels after acute treatment
with CsA
Expression of the rate-limiting enzyme in the synthesis of
dopamine, evaluated as ratio between (p)-TH and total TH
protein levels, was used as a marker of the dopaminergic ac-
tivity (Struntz and Siegel 2018). While protein levels of total
TH (F(2,89) = 0.906; p = 0.427; Fig. 3a) and p-TH (F(2,89) =
2.293; p = 0.128; Fig. 3b) did not differ between groups,
ANOVA showed an effect of treatment in the p-TH/TH ratio
(F(2,89) = 6.713; p = 0.0066; Fig. 3c). Post hoc analyses re-
vealed a significantly reduced ratio in the 20 mg group com-
pared to controls (p = 0.0036). In the striatum, however, nei-
ther protein levels of total TH (F(2,89) = 0.226; p = 0.799;
Fig. 3d) and p-TH (F(2,89) = 2.056; p = 0.155; Fig. 3e) nor
the p-TH/TH ratio (F(2,89) = 1.234; p = 0.312; Fig. 3f) dif-
fered between groups.
Prepulse inhibition of the acoustic startle response
after subchronic treatment with CsA
In the subchronic experiment, following daily injection with
CsA for 1 week, sensorimotor gating was impaired, as well
(ANOVA; [F(2,89) = 3.705; p = 0.028]). Compared to con-
trols, animals of the 20 mg/kg group displayed a reduced
mean PPI (average of all four prepulse conditions; p = 0.022;
Fig. 4b), whereas animals treated with the lower dose of
5 mg/kg did not differ from controls. As seen in the acute
experiment, ASR was not affected (ANOVA; [F(2,117) =
0.935; p = 0.409]; Fig. 4c).
Tyrosine hydroxylase levels after subchronic
treatment with CsA
However, in the subchronic experiment, ANOVA showed no
treatment effect on protein levels of total TH (F(2,89) = 0.617;
p = 0.549; Fig. 5a) and p-TH (F(2,89) = 2.620; p = 0.094; Fig.
5b), or of the p-TH/TH ratio (F(2,89) = 1.541; p = 0.2432; Fig.
5c) in the prefrontal cortex. Likewise, ANOVA showed no
group differences between protein levels of total TH
(F(2,89) = 0.065; p = 0.9375; Fig. 5d), p-TH (F(2,89) = 1.9;
p = 0.174; Fig. 5e), and p-TH/TH ratio (F(2,89) = 2.684; p =
0.0917; Fig. 5f) in the striatum.
Discussion
This study found that acute and subchronic treatment with the
calcineurin inhibitor and immunosuppressant CsA disrupted
PPI at the dose of 20 mg/kg. We also observed reduced p-TH/
TH ration in the prefrontal cortex following acute CsA treat-
ment, potentially indicative for downregulated dopamine syn-
thesis. These findings link impaired calcineurin signaling in
the CNS to the pathophysiology of neuropsychiatric symp-
toms as observed after treatment with psychomotor stimulant
drugs, characterizing therapy with calcineurin inhibitors as a
risk factor for developing neurobehavioral alterations.
Patients with schizophrenia display impairments in mea-
sures of attention, cognition, and sensorimotor gating (PPI)
(Geyer et al. 2001). Similar deficits can be induced
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experimentally in rodents using pharmacological manipula-
tions (Braff et al. 2001; Koch 1999; Swerdlow et al. 2000,
2001). We show that acute and subchronic treatment with
CsA resulted in impaired sensorimotor gating. This observa-
tion is consistent with findings, revealing diminished PPI in
rats after acute and long-term treatment with amphetamines
(Brunell and Spear 2006; Druhan et al. 1998; Fletcher et al.
2005; Hadamitzky et al. 2011; Mansbach et al. 1988; Tenn
et al. 2003), or after direct infusion of dopamine into the
mesolimbic dopamine system (Featherstone et al. 2007).
These present findings are also congruent with outcomes seen
in calcineurin-mutant mice. Among others, this forebrain-
specific calcineurin knockout also led to impairments in PPI
(Miyakawa et al. 2003; Zeng et al. 2001). Given that acute
Fig. 3 Western blot analysis of total tyrosine hydroxylase (TH) levels
af ter acute t rea tment wi th the calc ineur in inhibi tor and
immunosuppressant cyclosporine A (CsA; 5, 20 mg/kg). a Total TH, b
phosphorylated (p)-TH, and c p-TH/TH ratio in the prefrontal cortex; d
total TH, e p-TH, and f p-TH/TH ratio in the striatum of treated animals.
Representative blot images show total TH, p-TH, and β-actin. Data are
shown as scatter plot with mean ± SEM. Differences between groups are
indicated by asterisk (ANOVA, Bonferroni post hoc; **p < 0.01; n = 6–9/
group)
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exacerbation of psychotic symptoms in a schizophrenic pa-
tient was strongly related to therapy with the calcineurin in-
hibitor FK506 (Lin et al. 2007), these data together suggest a
link between altered calcineurin signaling in the CNS and the
development of neuropsychiatric symptoms (Lin et al. 2007;
Takao and Miyakawa 2006). However, effects after the dif-
ferent CsA treatment regimens were not consistent. While
acute CsA disrupted PPI at both doses of 5 and 20 mg/kg
(Fig. 2), subchronic treatment affected PPI only after daily
administration of CsA at the dose of 20 mg/kg (Fig. 4). This
may be attributed to the fact that 5 mg/kg CsA is considered as
low therapeutic dose, exerting rather moderate inhibition on
calcineurin. Apparently, these low dose effects are compen-
sated during a subchronic treatment regimen and thus ineffi-
cient to block central calcineurin signaling leading to behav-
ioral alterations. Studies revealed that deficits in PPI were
abolished by administering the typical antipsychotic drug
and dopamine D2 receptor antagonist haloperidol, pointing
towards central dopamine hyperfunctioning as one cause for
PPI disruption (Swerdlow et al. 1994; Swerdlow and Geyer
1993). Calcineurin is located downstream of the glutamate N-
methyl-D-aspartate (NMDA) receptor signaling pathway (Lin
et al. 2007; Takao and Miyakawa 2006) and it appears that
calcineurin regulates both dopaminergic (Greengard 2001)
and glutamatergic neurotransmission (Zeng et al. 2001).
Phosphorylation of TH stimulates production of dopamine,
but this enzyme is also rate limiting in the synthesis of this
neurotransmitter (Daubner et al. 2011; Harada et al. 1996;
Lindgren et al. 2000). Levels of TH and p-TH or rather the
ratio of p-TH/TH may therefore be used as a marker for re-
gional dopaminergic activity. We here show that impaired PPI
following acute treatment with 20 mg/kg was also associated
with decreased activity of TH in the prefrontal cortex (Fig. 3).
These findings are consistent with studies, showing that psy-
chomotor stimulants, which increased dopamine release from
the ventral tegmental area and which in turn altered the striatal
dopaminergic system (Sulzer 2011), decreased activity of TH
in rats following acute drug exposure (Jedynak et al. 2002;
Leonard 1977). Vice versa, central dopamine receptor blocker
such as chlorpromazine and haloperidol increased activity of
this enzyme (Leonard 1977). Moreover, it was shown that
CsA administration mimicked cocaine’s actions and potenti-
ated the locomotor responses to cocaine (Addy et al. 2008),
suggesting that both compounds modulate their action at least
partially via the same target structure, CaN.
However, surprisingly, we detected reduced TH activity
neither in the striatum as seen after cocaine administration
(Jedynak et al. 2002) nor in the striatum and the prefrontal
cortex following subchronic treatment with CsA (Figs. 3
and 4). Regarding subchronic treatment, it may be possible
that TH activity has potentially changed due to constant
calcineurin blockade, since dopamine levels are rather
quicker affected by CsA, as seen following acute treat-
ment. At least, this was the case in a microdialysis study
that evaluated effects of methamphetamine on extracellular
levels of dopamine (Dobbs and Mark 2008). Given that the
analyses of the striatum did not subdivide into the dorsal
(caudate nucleus) and the ventral part (nucleus accum-
bens), potential effects on TH activity on either one of
these structures may have been missed, in general.
Nevertheless, we hypothesize that reduced TH activity fol-
lowing acute administration of CsA reflects (homeostatic)
downregulation of catecholamine synthesis, as seen with
psychostimulants such as cocaine. Conclusively, as also
discussed as one traditional theory of schizophrenia path-
ophysiology (Abi-Dargham and Moore 2016; Laruelle
Fig. 4 Subchronic treatment with the calcineurin inhibitor and
immunosuppressant cyclosporine A (CsA) on prepulse inhibition (PPI)
of the acoustic startle response (ASR). The line plot shows percent PPI as
a function of different prepulse intensities above background (a). Daily
injections with the calcineurin inhibitor for 7 days significantly
diminished mean PPI in the 20 mg/kg group (b). At both doses, ASR
was not affected (c). Data are shown as scatter plot with mean ± SEM.
Differences between groups are indicated by asterisk (ANOVA,
Bonferroni post hoc; *p < 0.05; n = 7–10/group)
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et al. 2003), we assume that CsA-induced diminished calcine-
urin signaling increased cortical dopamine turnover, responsi-
ble with the observed PPI deficit (Carey et al. 1995).
Conclusion and future directions Patients suffering from au-
toimmune diseases or who underwent organ transplantation
require regular, often life-long, immunosuppressive medica-
tion. It is assumed, and proven in some cases, that treatment
with certain immunosuppressive drugs is frequently associat-
ed with the emergence of central side effects. The present
study confirmed this hypothesis, showing that acute and sub-
chronic treatment with the calcineurin inhibitor CsA led to
deficient sensorimotor gating. Additionally, reduced TH ac-
tivity was observed in the prefrontal cortex, indicating that
central blockade of calcineurin by CsA possibly affected do-
pamine turnover.
Fig. 5 Western blot analysis of total tyrosine hydroxylase (TH) levels
after subchronic treatment with the calcineurin inhibitor and
immunosuppressant cyclosporine A (CsA; 5, 20 mg/kg). a Total TH, b
phosphorylated (p)-TH, and c p-TH/TH ratio in the prefrontal cortex; d
total TH, e p-TH, and f p-TH/TH ratio in the striatum of treated animals.
Representative blot images show total TH, p-TH, and β-actin. Data are
shown as scatter plot with mean ± SEM (ANOVA, Bonferroni post hoc;
n = 8–10/group)
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However, a limitation of the study is that besides other
markers for dopaminergic activity only activity of TH was
measured.We initially intended to verify calcineurin blockade
by blotting NFAT, but this approach failed due to limited
detection profile. Despite the fact that following amphetamine
administration increased extracellular dopamine concentra-
tions were found in both striatal areas, the nucleus accumbens
(ventral part) and the caudate nucleus (a dorsal part), these
effects were more pronounced in the accumbens (Di Chiara
and Imperato 1988). Similarly, injections of the dopamine
antagonist haloperidol into the accumbens abolished
amphetamine-induced locomotor activity, while injections in-
to caudate had no effect (Pijnenburg et al. 1975). Against this
background, a more detailed analysis of dorsal vs. ventral
striatum or analyses of dopamine turnover and dopamine
transporter expression (DAT) would have been advantageous.
Microdialysis studies may therefore extend these initial find-
ings by investigating the exact role of dopamine in distinct
brain areas. Given that rodent models have demonstrated cog-
nitive dysfunctions due to aberrant dopaminergic signaling in
the medial prefrontal cortex (Castner et al. 2004), future stud-
ies may also address this issue by analyzing whether immu-
nosuppressive compounds affect working memory in tests
such as the radial maze, the Barnes maze, or the Morris water
maze (Bendix et al. 2019).
Even though the exact mechanisms behind the observed
neurobehavioral changes of CsA are still unclear, our findings
support experimental and clinical evidence linking impaired
calcineurin signaling in the CNS to alterations in dopamine
activity and PPI deficits. Importantly, data regarding pharma-
cological options of treating neuropsychiatric side effects of,
e.g., transplant patients are very sparse. It is known, however,
that CaN-free immunosuppression with everolimus in heart
transplant recipients significantly improvement CaN-induced
side effects (Rothenburger et al. 2007). However, despite the
availability of a wide range of small-molecule drugs with less
side effects (Bosche et al. 2015), calcineurin inhibitors such as
CsA are still first-choice drugs for the treatment of several
immune-associated diseases. The present data indicate that
therapy with calcineurin inhibitors may be classified as a risk
factor for developing neuropsychiatric alterations, thereby ad-
dressing the importance for investigating exact neurobiologi-
cal mechanisms of action of immunotherapeutic drugs, fre-
quently used in daily clinical routine.
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